Merck CEO Clark Brings Managed Care Expertise To Post; Gilmartin Retires
This article was originally published in The Pink Sheet Daily
Executive Summary
Richard Clark's appointment signals the importance Merck is placing on managed care ahead of the January 2006 start of the Medicare drug benefit. Merck also is highlighting Clark's manufacturing expertise, but acknowledges he will rely on Merck Research Labs President Peter Kim for advice on R&D strategy.
You may also be interested in...
Merck Begins Cuts With Manufacturing, More Cost Reductions To Follow
The company suggests future restructuring efforts could address R&D, marketing and sales after unveiling the first phase of its restructuring initiative.
Merck Begins Cuts With Manufacturing, More Cost Reductions To Follow
The company suggests future restructuring efforts could address R&D, marketing and sales after unveiling the first phase of its restructuring initiative.
Merck Completes Vioxx-Related Cost Reduction Program
Merck's third quarter financial results reflect an $80 mil. charge associated with the company's post-Vioxx global cost reduction program, CEO Richard Clark said during a third quarter earnings call Oct. 24